News
RLMD
3.910
+1.03%
0.040
Weekly Report: what happened at RLMD last week (0415-0419)?
Weekly Report · 1d ago
Bullish Relmada Therapeutics Insiders Loaded Up On US$695.2k Of Stock
Relmada Therapeutics, Inc. Insiders bought US$387k worth of shares in the last year. The biggest single purchase was by CEO & Director Sergio Traversa at a price of US$4.00 per share. In the last 12 months, RelmadaTherapeutics insiders have purchased US$663k of shares. It's good to see the company has bought shares at near the current price. But the company may not be the best stock to buy. You can see the insider transactions of RelmADA Therapeutic in the UK.
Simply Wall St · 3d ago
Weekly Report: what happened at RLMD last week (0408-0412)?
Weekly Report · 04/15 09:18
Weekly Report: what happened at RLMD last week (0401-0405)?
Weekly Report · 04/08 09:20
Weekly Report: what happened at RLMD last week (0325-0329)?
Weekly Report · 04/01 09:19
Weekly Report: what happened at RLMD last week (0318-0322)?
Weekly Report · 03/25 09:19
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Relmada Therapeutics plans to report results from the phase 3 Reliance II study of REL-1017 in H2 2024. The stock of RLMD has dropped 20% since a previous article on the potential for a run up into the results. The company has cash to complete its current studies.
Seeking Alpha · 03/21 22:57
Optimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stability
TipRanks · 03/21 06:45
Optimistic Outlook for Relmada Therapeutics: A Comprehensive Analysis and Buy Rating
TipRanks · 03/21 06:17
U.S. RESEARCH ROUNDUP-Dick's Sporting Goods, Nvidia, PVH
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Dick's Sporting Goods, Nvidia and PVH are among the companies. Hilton Worldwide Holdings and Cisco also raise their targets for the day. Some analysts raised their target prices for the companies on Wednesday.
Reuters · 03/20 07:14
RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023
Relmada Therapeutics reported earnings per share of -84 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -83 cents. Relmada reported results for the last quarter of 2013.
Investorplace · 03/20 00:52
Relmada Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Relmada Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 84 cents per share. The mean expectation of five analysts was for a loss of 83 cents. Reported revenue was zero; analysts expected zero. Shares had risen by 33.3% this quarter.
Reuters · 03/19 21:02
Relmada Therapeutics Q4 EPS $(0.84) Misses $(0.83) Estimate
Benzinga · 03/19 20:33
Recap: Relmada Therapeutics Q4 Earnings
Relmada Therapeutics reported its Q4 earnings on March 19. The company missed estimates by -1.0%. The company's revenue was down $0 from the same period last year. Last quarter the company beat on EPS by $0.18 and the share price went up.
Benzinga · 03/19 20:30
Relmada Therapeutics GAAP EPS of -$0.84
Relmada Therapeutics reports Q4 GAAP EPS of -$0.84. Net cash used in operating activities for the three months ended December 31, 2023, totaled $10.3 million compared to $35.9 million for the same period in 2022.
Seeking Alpha · 03/19 20:22
*Relmada Therapeutics: Provides Corporate Update and Reports 4Q and Full-Yr 2023 Fincl Results
Dow Jones · 03/19 20:20
*Relmada Therapeutics: As of Dec 31, 2023, Had Cash, Cash Equivalents, Short-Term Investments of Approximately $96.3M, Compared to Cash, Cash Equivalents, Short-Term Investments of Approximately $148.3M at Dec 31, 2022 >RLMD
Dow Jones · 03/19 20:20
BRIEF-Relmada Therapeutics Q4 EPS USD -0.84
Reuters · 03/19 20:15
Press Release: Relmada Therapeutics Provides -2-
Relmada Therapeutics, Inc. Reported its financial results on December 31, 2013. The company has a total of $1.2 billion in assets and $7.1 billion in liabilities. Relmada is a subsidiary of a company that is a member of the Nasdaq-listed Nasdaq Group.
Dow Jones · 03/19 20:15
Press Release: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results. The Company is a late-stage biotechnology company addressing diseases of the central nervous system. Relmada's Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder continues to advance. The company will host a conference call today to discuss its financial results.
Dow Jones · 03/19 20:15
More
Webull provides a variety of real-time RLMD stock news. You can receive the latest news about Relmada Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.